乳腺癌内分泌治疗耐药的研究进展。
Headway in resistance to endocrine therapy in breast cancer.
机构信息
Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
出版信息
J Thorac Dis. 2010 Sep;2(3):171-7. doi: 10.3978/j.issn.2072-1439.2010.02.03.9.
Abstract
Resistance to endocrine therapy is the major problem for ERα(+) breast cancer patients. Research in endocrine resistance, mainly based on breast cancer cell lines and transplantation animal models, has indicated that phosphorylation of estrogen receptors, high expression of SRC and high activation of ErbB/MAPK pathway are the 3 main mechanisms for occurrence of endocrine resistance. Restoration of ER expression and exploration of inhibitors to various biological targets are the 2 promising ways to solve this problem. Further research is needed to deeply explore relevant mechanisms and resolvents so as to guide clinical practice.
摘要
内分泌治疗耐药是 ERα(+)乳腺癌患者面临的主要问题。内分泌耐药相关研究主要基于乳腺癌细胞系和移植动物模型，提示雌激素受体磷酸化、 SRC 高表达和 ErbB/MAPK 通路持续激活是内分泌耐药发生的 3 个主要机制。恢复 ER 表达和探索针对各种生物学靶点的抑制剂是解决这一问题的 2 种有前途的方法。需要进一步深入研究相关机制和解决方法，以指导临床实践。
相似文献
1
Headway in resistance to endocrine therapy in breast cancer.
J Thorac Dis. 2010 Sep;2(3):171-7. doi: 10.3978/j.issn.2072-1439.2010.02.03.9.
2
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.
3
Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.
Cancer Biol Ther. 2012 Sep;13(11):1026-33. doi: 10.4161/cbt.20992. Epub 2012 Jul 24.
4
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21.
5
AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.
6
The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.
7
Significance of ER-Src axis in hormonal therapy resistance.
Breast Cancer Res Treat. 2011 Nov;130(2):377-85. doi: 10.1007/s10549-010-1312-2. Epub 2010 Dec 24.
8
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Endocr Relat Cancer. 2005 Dec;12(4):721-47. doi: 10.1677/erc.1.00857.
9
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
PLoS One. 2016 Jun 16;11(6):e0157397. doi: 10.1371/journal.pone.0157397. eCollection 2016.
10
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy.
Biol Proced Online. 2018 Sep 11;20:17. doi: 10.1186/s12575-018-0082-9. eCollection 2018.
引用本文的文献
1
New Advances in Targeted Therapy of HER2-Negative Breast Cancer.
Front Oncol. 2022 Mar 4;12:828438. doi: 10.3389/fonc.2022.828438. eCollection 2022.
2
The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.
Transl Cancer Res. 2021 Mar;10(3):1193-1203. doi: 10.21037/tcr-20-1760.
3
Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Cancer Manag Res. 2016 Jul 11;8:85-94. doi: 10.2147/CMAR.S98249. eCollection 2016.
4
Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2.
Neoplasia. 2015 Mar;17(3):279-88. doi: 10.1016/j.neo.2015.01.005.
5
The prevalence and correlates of breast cancer among women in Eastern China.
PLoS One. 2012;7(6):e37784. doi: 10.1371/journal.pone.0037784. Epub 2012 Jun 18.
6
Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells.
Tumour Biol. 2012 Oct;33(5):1403-10. doi: 10.1007/s13277-012-0388-1. Epub 2012 Apr 14.
7
Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
Tumour Biol. 2012 Oct;33(5):1349-62. doi: 10.1007/s13277-012-0383-6. Epub 2012 Apr 11.
8
The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro.
Tumour Biol. 2012 Aug;33(4):1159-67. doi: 10.1007/s13277-012-0358-7. Epub 2012 Feb 29.
9
Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer.
Tumour Biol. 2012 Feb;33(1):63-71. doi: 10.1007/s13277-011-0246-6. Epub 2011 Oct 4.
10
Dysregulated expression of dicer and drosha in breast cancer.
Pathol Oncol Res. 2012 Apr;18(2):343-8. doi: 10.1007/s12253-011-9450-3. Epub 2011 Sep 7.
本文引用的文献
1
Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Cancer Biol Ther. 2009 Aug;8(16):1550-8. doi: 10.4161/cbt.8.16.8954.
2
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.
3
ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers.
J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):67-78. doi: 10.1007/s10911-009-9113-0. Epub 2009 Mar 5.
4
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404.
5
Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Cancer Res. 2008 Sep 1;68(17):7083-9. doi: 10.1158/0008-5472.CAN-08-0739.
6
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Breast Cancer Res Treat. 2009 May;115(1):57-67. doi: 10.1007/s10549-008-0058-6. Epub 2008 May 21.
7
The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.
J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):181-94. doi: 10.1007/s10911-008-9084-6. Epub 2008 May 10.
8
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
Breast Cancer Res Treat. 2009 Mar;114(2):263-75. doi: 10.1007/s10549-008-0011-8. Epub 2008 Apr 14.
9
Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
Cancer. 2008 Feb 1;112(3 Suppl):679-688. doi: 10.1002/cncr.23191.
10
Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Clin Cancer Res. 2007 Dec 1;13(23):7029-36. doi: 10.1158/1078-0432.CCR-07-0587.
Zotero 插件